hlx17
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Apr 27, 2025 (NCT06847334)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07160335 | Phase 1 | Sep 26, 2025 | Shanghai Henlius Biotech |
| NCT06847334 | Phase 3 | Apr 27, 2025 | Shanghai Henlius Biotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Henlius Biotech | For profit | 2 | 2 | 2 | 2025 |
1 organizations
Page 1 / 1